What are patients’ and health professionals’ experiences of access to palliative care medicines in different models of community care provision? Systematic review and narrative synthesis.

Mizue Ogi, School of Health Sciences, University of Southampton, UK, ORCID iD: 0000-0003-3096-5850

Natasha Campling, School of Health Sciences, University of Southampton, UK, ORCID iD: 0000-0002-4158-7894

Jacqueline Birtwistle, Academic Unit of Palliative Care, Leeds Institute of Health Sciences Leeds University School of Medicine, Leeds, UK ORCID iD 0000-0002-6083-589X

Alison Richardson, School of Health Sciences, University of Southampton, & University Hospital Southampton NHS Foundation Trust, Southampton, UK ORCID iD: 0000-0003-3127-5755

Michael I. Bennett, Academic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK ORCID iD 0000-0002-8369-8349

Miriam Santer, School of Primary Care, Population Sciences and Medical Education (PPM) University of Southampton, Southampton, UK. ORCID iD 0000-0001-7264-5260

Sue Latter, School of Health Sciences, University of Southampton, UK, ORCID iD: 0000-0003-0973-0512

Corresponding author: Sue Latter; Building 67 Room 4065, School of Health Sciences, University of Southampton SO17 1BJ, United Kingdom, sml@soton.ac.uk T: +44 2380597959

Keywords: Palliative care; community; medicines; access; service delivery.

Word count: 4905
ABSTRACT (249/250 words)

Background Providing palliative care patients living at home with timely access to medicines is critical to enable effective symptom management, minimise burden and reduce unplanned use of healthcare services. Little is known about how diverse community-based palliative care models influence medicines access.

Objective To produce a critical overview of research on experiences and outcomes of medicine access in community-based palliative care models of service delivery through a systematic review and narrative synthesis.

Methods MEDLINE, CINAHL, Embase, PsycINFO, Cochrane Library databases and grey literature were systematically searched for all types of studies. Study quality was assessed using the Mixed Method Appraisal Tool; a narrative synthesis was used to integrate and summarise findings.

Results 3331 articles were screened; 10 studies were included in the final sample. Studies included a focus on community pharmacy (n=4), hospice emergency medication kits (HEMKs) in the home (n=3), specialist community nurse prescribers (n=1), General Practice (n=1) and one study included multiple service delivery components. Community pharmacy was characterised by access delays due to lack of availability of medicine stock and communication difficulties between the pharmacy and other healthcare professionals. HEMKs were perceived to reduce medicines’ access time out-of-hours, and speed symptom control. However, the majority of studies comprised small, local samples, largely limited to self-reports of health professionals. There was a lack of data on outcomes, and no comparisons between service delivery models.
Conclusions Further research is required to understand which models facilitate rapid and efficient access to medicines for community-based palliative care patients.
What are patients’ and health professionals’ experiences of access to palliative care medicines in different models of community care provision? Systematic review and narrative synthesis.

INTRODUCTION

Population ageing, together with the home being many people’s preferred place of death,[1] has increased the need for community-based palliative care, including access to medicines. Timely patient access to medicines in the last year of life (end-of-life (EoL)) is critical for control of symptoms managed at home.[2] Patients may have a complex range of clinical issues related to their condition, and fluctuating symptoms, including severe pain, can be difficult to control, requiring frequent readjustment of medication.[3] The process of medicines access for symptom control can be a lengthy one, including obtaining a prescription for a medicine, ensuring it is dispensed correctly, and supplied, together with information that enables patients and carers to manage medicines effectively in the home. Evidence from our previous studies suggests that for patients and carers receiving community-based palliative care, the experience of accessing medicines is often a considerable burden, involving multiple professionals and including a complex process of attaining and managing controlled drugs, such as opioids.[4] In the United Kingdom (UK), the provision of community palliative care is characterised by heterogenous models of service delivery.[5] Care can be delivered by generalist or specialist health professionals, or a mix of both; patients may or may not receive care from specialist palliative care nurses, and these or other generalist nurses may or may not be trained to independently prescribe medicines directly to patients. Nurses and pharmacists in the UK have amongst the most extensive prescribing rights in the world, including the prescription of controlled drugs. The introduction of these prescribing rights was driven by the need to
increase speed of access to medicines for patients and make best use of health professionals’ skills.[6] Additionally, in some areas community pharmacies may hold enhanced stocks of palliative care medicines and extended opening hours as part of specially commissioned services. Other more recent initiatives in service delivery may also impact the experience of medicines access: a policy drive to increase the availability of out-of-hours telephone advice for palliative care patients; and pharmacists with a prescribing qualification are increasingly employed in General Practices in England in a move to diversify primary care workforce skill mix.[7] Paramedics were also granted prescribing authority in the UK in 2019, who may be a first point of call for patients in an emergency.

However, little is known about the impact of these models of service delivery on patients’ experience of accessing EoL medicines in the community or the relative merits of each approach. Questions such as which models work best, do recent initiatives improve speed and lessen the burden on patients working to access medicines, and what factors support or challenge access experiences, remain unanswered.

The aim of the systematic review reported here was to produce a critical overview of existing research on experiences and outcomes of medicines access associated with models of service delivery of community-based EoL care. Our aim was to systematically search for and review international research studies for evidence of: a) patient, carer and health professional experience of medicines access within the context of different models of service delivery b) patient and carer outcomes associated with medicines access experiences. In this review, medicines access was defined as prescribing, dispensing, supplying and associated information provision about medicines.
This systematic review formed part of a larger study entitled ‘Accessing medicines at end-of-life: a multi-stakeholder, mixed-method evaluation of service provision’ (ACcess To MEDicine (ActMed) study; NIHR funded project [HS & DR 16/52/23]).

(https://www.journalslibrary.nihr.ac.uk/programmes/hstdr/165223/#/)

METHODS

The systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines.[8] The review is registered on the PROSPERO database (International Prospective Register of Systematic Reviews) Ref No CRD42017083563 (http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017083563).

Search strategy

A search strategy was developed based on the research question, ‘What are the experiences and outcomes of medicine access for patients and carers receiving community-based models of palliative care, during the last year of life?’ The search was conducted as described below to include any studies related to this focus.

Information sources

(1) Database search: Four electronic databases (MEDLINE, PsycINFO, CINAHL and EMBASE) were searched for published literature from January 2006 to March 2019 using keywords, synonyms and Boolean operators. An example of the search strategy is shown in online supplemental material Table 1.

(2) Citation search: A citation search was conducted on the included articles for further relevant material.
(3) Databases of systematic reviews: the Cochrane Library database was searched in order to acquire relevant systematic reviews published between January 2006 - June 2019.

(4) Ongoing systematic reviews: To obtain information on relevant ongoing systematic reviews, PROSPERO was searched for reviews registered between January 2006 - June 2019.

(5) Relevant research in progress: To gain information regarding relevant ongoing trials, ISRCTN and Clinical trial.gov were searched for trials registered between January 2006 - June 2019.

(6) Experts’ lists: To obtain further relevant published or grey literature, members of the Scientific Steering Committee of the ACcess To MEDicine (ActMed) study were asked for their top five references on this issue.

(7) Grey literature: To minimise the impact of publication bias, grey literature sources (British Library, King’s Fund, NDLTD (Networked Digital Library of Theses and Dissertations), NICE (National Institute for Health and Care Excellence) Evidence Search, Nuffield Trust, OpenGrey and Google) were searched for unpublished materials between January 2006- June 2019.

Study selection

Eligibility

Inclusion and exclusion criteria are summarised in Figure 1. As described above, medicines access was defined as prescribing, dispensing, supplying and providing associated information about medicines; EoL was defined as the last year of life. The search period start date was 2006 because this was the point at which nurses and pharmacists in the UK gained the legal ability to independently prescribe any medicine from the British National Formulary.[9]
Children and young people under 18 years of age were excluded as our focus was on access to medicines for adults living at home.

Selection process
Studies were selected for inclusion using a two-step process: one researcher (MO) screened titles (and abstracts when necessary) to remove duplicates, using data management software (EndNote, X8.2, Clarivate Analytics Co.,Ltd). Following de-duplication, titles and abstracts were screened to determine study eligibility. To ensure the validity of the process, one reviewer (MO) and a second reviewer (NC) each independently screened a random sample of 10% of abstracts; screening results were double-checked by a third reviewer (SL). After resolving disagreements and achieving consensus, the remainder of screening was undertaken by a single author (MO). Following initial decisions on papers for inclusion, two review authors (MO and SL) each independently reviewed full-text articles against all inclusion and exclusion criteria and resolved disagreements through discussion in order to achieve consensus.

Data extraction and quality appraisal
Data extraction was conducted for each eligible study by a single reviewer (MO) and checked against the manuscript by another reviewer (SL). Quality appraisal was undertaken using the mixed-method appraisal tool (MMAT), which includes tools for different study designs and is therefore appropriate for systematic reviews that include qualitative, quantitative and mixed-method research studies.[10] Appraisal was undertaken by a single reviewer (MO), recorded on a data extraction sheet, and checked by another reviewer (SL). Data management software (EndNote) was used to organise the search results and references.
**Synthesising and interpreting results**

The search identified that studies included qualitative, quantitative and mixed-method research. Thus, a framework for a mixed studies review was utilised, with thematic analysis of qualitative data within a data-based convergent synthesis design.[11] In this design, qualitative and quantitative data can be analysed and synthesised together. Overlaying this however, and in keeping with the study focus, we structured the review according to models of service delivery that we found in the literature reviewed: community pharmacy services; General Practitioners (family doctors); community specialist nurse independent prescribers; and hospice emergency medication kits.

**RESULTS**

The electronic database search produced 3627 records and 19 records were identified by expert consultation, as shown in the PRISMA flow diagram in Figure 2. Ten studies were included in the review: five quantitative studies, four qualitative studies, and one mixed-methods study (online supplemental material Table 2). One study (Latham and Nyatanga 2018) was reported as a short series over two editions of a journal; [12,13] these were linked together for the purposes of the current review.

All studies were from economically developed countries: the UK, Republic of Ireland, the United States, Australia and Japan. The majority of the included studies used small sample sizes and were locality-based studies limited to a few districts or institutions, with the exception of one nationwide study in Japan. In general, the quality of each study was variable in terms of methodological rigour; limitations were that samples were often insufficiently described, making conclusions about generalisability or transferability difficult, the
development of data collection tools often lacked detail and surveys had low response rates, making response bias difficult to rule out. There were no RCTs or large-scale studies (details of quality assessments are shown in online supplemental material Table 3).
Medicines access and community pharmacy services

Four studies focused exclusively on investigating medicines access experiences related to community pharmacy[14-17] of which two studies[15,17] included pharmacies providing enhanced or commissioned palliative medicine services (in the UK, this typically involves keeping a core stock of palliative medicines and extended opening hours for access). Two further studies included evaluation of community pharmacy medicines access as part of investigating the broader model of community service provision for patients receiving home-based specialist palliative care.[18-19] Two studies focused exclusively on the perspectives of community pharmacists in providing access,[14-15] whilst three studies also included patients and other health professionals,[17-19] and Bennie et al (2013) focused solely on patients’ views of community pharmacy access.[16]

The access experience

Overall, findings from all six studies revealed a picture of delays and problems with accessing medicines from community pharmacies; these were focused on pharmacy stock of medicines, and on information provision.

Pharmacy stock of palliative care medicines

Ise et al (2010) provide some quantitative data on access, indicating less than comprehensive provision, with 77% of the 1036 community pharmacies in their nationwide survey in Japan holding a ‘narcotics’ (opioid) licence and only 50% reporting involvement in monthly provision of opioids.[14] It is unclear why the other 23% of pharmacies did not hold a licence or how this affected the patient experience of accessing opioids but Ise et al comment that a system whereby all community pharmacies can supply opioids to all patients who need them has clearly not been established. Certainly, lack of community pharmacy stock of palliative care medicines generally is also reported as problematic in other studies.[15,17-18] Miller found that although 44/55 (80%) of the patients/carers surveyed reported receiving palliative medicines on their first visit, 10/54 (1 missing data, 19%) had to travel to more than one pharmacy before accessing the medicines and 40/55 (73%) reported that the medicines were ‘needed urgently’.[17] Although not measured quantitatively, community pharmacists in Akram et al’s study of four localities in Scotland also reported delays in being able to provide palliative care medicines, and these pharmacies were part of an enhanced commissioned service and specialist network to provide these medicines to patients in the community.[15] On the other hand, Lucey et al’s study, a systems analysis of obtaining medications for patients under the care of a specialist palliative home care provider, reported that in 54% of 22 patient-reported medicine changes during the study period, medication was received without delay. However, the numbers of patients were small (n=12).[18] Nurses’ reports in this study
also showed only 12 instances of delays across 57 patients over a 12 week period - the majority of
these being over 48 hours wait.[18] The main reason for delays was due to no stock in the
community pharmacy.[18] The overall number of medicines access episodes that nurses reported on
is not clear, but 12 delays over 12 weeks for 57 patients seems a relatively small number of
delays.[18]

*Information provision*

Data on community pharmacy information provision for patients is available in three
studies,[14,16,19] and again, shows there is scope for improvement. Patients and carers in Bennie et
al’s focus groups saw the pharmacist as a source of medicines information (as well as GPs) if they
had a relationship with them. However, some reported little contact with a community pharmacist
and overall knowledge of services offered was poor, with patients often acquiring knowledge in an
unplanned way through family / friends or when in a crisis situation.[16] Patients and carers wanted
a more proactive role from pharmacists, in particular regarding prescription and supply processes of
controlled drugs or when a new medicine was prescribed.[16] The sample in this study was small: 14
patients and 13 carers from one city in Scotland.[16] Nevertheless, findings from Ise et al’s national
survey also highlight gaps in information provision: 50% of the 1036 pharmacists in their study
reported that they did not counsel patients about their palliative care medicines, primarily because
they lacked information about the patient (e.g. disease status and awareness of illness and opioids),
and less than 5% had a room to counsel the patient privately.[14] In Australia, carers and patients
felt that sometimes the information provided was inadequate for them to manage their medications
at home appropriately.[19]

Influences on accessing medicines from community pharmacies

*Communication, collaboration and education*

Four studies report on influences that challenge or support the access process.[14-15,17-18] Many
of these are concerned with communication between the pharmacist and other members of the
healthcare team. Communication with the pharmacy was reported as problematic, causing delays in
supplying medicines, through a mis-match between prescriptions received and stocks held[15]
and/or a lack of information on the palliative care status of the patient.[14-15,17] The latter was
either due to the pharmacist seeing unfamiliar patients who had been referred by another network
pharmacist[15] or health professionals’ reluctance to share information.[17] A finding reported by
both studies that included enhanced or commissioned services also related to
communication:[15,17] medicines access was adversely affected by health professionals’ lack of
knowledge about these services. Miller (2017) concludes that ‘poor healthcare professional (HCP)
knowledge of which pharmacies stock palliative medicines meant patients and their families were not always able to access medicines promptly’ and that HCPs need to routinely be made aware of such services and their locations.[17] Similarly, patients and carers in Bennie et al.’s study also reported a lack of awareness of more general pharmacy services. Pharmacists in Akram et al.’s (2012) study also reported that communication was disrupted when patients transferred between secondary and primary care settings, affecting prescriptions and the ability to swiftly supply medicines needed.[15]

Little data were available on factors supporting good access, related to the fact that studies highlighted poor access experiences. However, pharmacists in one study stated that pre-emptive communication from community nurses about medicines likely to be required by patients was helpful, as well as being part of a network of pharmacists, where medicines and advice could be accessed.[15]

Akram et al (2012) also found community pharmacists perceive better training of counter staff and of locum pharmacists is needed, as well as resources for pharmacists to support clinical practice.[15] Additionally, Miller’s (2017) focus group interview highlighted that community pharmacists often have limited experience and knowledge about palliative care medicines.[17] Furthermore, Kuruvella et al.’s findings indicated GPs unfamiliar with palliative care medicine needed support, and a palliative care specialist pharmacist could be valuable for such GPs and be a integral role for a community palliative care service.[19]

**Practical problems with palliative medicines stock and couriing medicines**

Miller (2017) found pharmacists reported practical difficulties keeping palliative medicines in stock - for example, secure storage space and the wide range of opioid dosage requirements for individual patients.[17] 70% of pharmacists in Ise et al.’s (2010) survey also said that being able to have a swift supply from, and ability to return opioids to wholesalers would be useful, as well as being able to get stock from other local pharmacies.[14] Further obstacles were also identified: 33% (19) of pharmacists completing questionnaires in Lucey et al.’s study reported difficulties in accessing stock and 49% that medicines not being on state reimbursement schemes caused delays.[18] In addition, the authors report the other main factor causing delays was no one to courier prescriptions /medication to and from GP, pharmacy and patient. The difficulty of picking up medications from community pharmacy by patients or carers were also noted by Miller (2017).[17] In another study, families’ involvement in collecting prescription or medicines and delivery services seemed to be helpful, though the latter was not always available and they were a financial burden.
for some patients when delivery was not free of charge.[19] Additionally, patients and families receiving medicines in this way seldom interacted directly with pharmacists.[19]

**Outcomes of community pharmacy medicines access**

There is little data on outcomes reported in the studies reviewed. One study reported that commissioned service pharmacies stocking an agreed list of palliative care medicines could shorten the time required to obtain urgently needed palliative medication compared to medication being provided by a non-commissioned service pharmacy.[17] The median time taken for accessing urgent palliative care medicines was significantly longer for non-commissioned service pharmacies (5 hours) compared to pharmacies commissioned to hold stock of palliative care medicines (10 minutes p=0.002).[17] Additionally, compiling tailored lists of palliative care medications through communication between pharmacies and GPs resulted in a similar time saving in commissioned pharmacies.[17] However, the impact of this on outcomes such as symptom control, patient and carer distress or use of emergency health services was not evaluated.

**General practitioners (family doctors)**

Only one study included data on GPs’ experiences of providing medicines access, focusing on delays and the causes of these.[18] Questionnaires were sent to 268 GPs in one city, asking them to select the most common causes of delay from a pre-specified list.[18] 111 questionnaires were returned (41% response rate).[18] No delay was reported by 34% of GPs.[18] The most commonly cited factor causing delay was the need to clarify the advice given by the homecare team (30.6%), followed by the inability of someone to collect the prescription (23.4%) and 18.9% of respondents reported the patient being unable to attend the surgery as a cause of delay.[18]

**Community specialist nurse independent prescribers**

One study conducted interviews with six independent nurse prescribers employed as community palliative care clinical nurse specialists, in an interpretive phenomenological study.[12-13] The study was conducted in one region in England and aimed to understand the lived experience of these nurses prescribing for palliative care patients in the community.[12] They found the most significant perceived benefit of nurse prescribing, reported by all six nurses, was that it enabled patients to access medication quickly, particularly near the end of their life, leading to effective symptom management.[13] The majority of the nurses also considered that it was during out-of-hours that the ability to prescribe independently had the most impact, preventing delays by avoiding the need to call an out-of-hours doctor, which could reportedly take many hours.[13] The authors conclude: ‘The
ability of community palliative care clinical nurse specialists to prescribe can facilitate rapid access to medicines, particularly during out-of-hours periods.'[13] (p133)

Hospice emergency medication kits¹

Three studies from the United States evaluated the outcome of hospice emergency medication kits (HEMKs) regarding use, impact and cost.[20-22] HEMKs are typically ordered by a physician on referral to home hospice service, and kept in the patient’s home, to allow the patient access to small quantities of medication that can be administered immediately upon nurse instruction.[20-22] Emergency medication kits contain sufficient medications for 12 to 72 hours, thus avoiding the immediate need for pharmacy and physician involvement after-hours.[21] All studies included an evaluation of the perceived impact of HEMKs, which shed light on their effect on access to medicines. In all studies, clinicians providing care were asked about HEMKs’ impact on unplanned healthcare resource use; the majority considered that kits averted use of other services. For example, 93% of the 78 home hospice nurses completing a questionnaire survey in one study reported that an emergency department visit or hospitalisation was avoided by having a kit in the home, with 26.1% reporting this was ‘often’ and 40.6% ‘very often’. [22] Clinician views on helpfulness and patient satisfaction were also positive across the two studies measuring this, with 59% of nurses considering HEMKs to be helpful 100% of the time ;[22] and 100% (n=13) of the hospices using HEMKs in the other study reporting it increased both patient and nurse satisfaction.[21] In a comparison between a hospice using HEMKs for some patients and one not using them at all, Walker and McPherson (2010) also report the after-hours nurses perceived caller (patient/family) satisfaction was significantly higher in hospice patients with a kit compared to both the non-kit hospice patients and the HEMKs-using hospice patients without a kit (95%, 75%, and 82%, respectively; P < .001).[21] One study also measured the impact of HEMKs on perceived symptom relief time.[21] Nurses in the hospice using HEMKs estimated 56% of after-hours callers received symptom relief within 30 minutes, whereas nurses reported none of their callers from the hospice without kits were treated satisfactorily in less than 30 minutes.[21]

Overall, whilst HEMKs were found to have a positive impact on a number of medicines access indicators in all three studies - including perhaps notably, shorter time to symptom relief and

¹ HEMKs were intended for use in any emergency across an extended period at end of life and contained a wide range of medicines, including for example, antibiotics. We therefore considered these studies met our inclusion criteria, and were not equivalent to ‘just-in-case’ boxes, which were excluded from the review.
reduced use of emergency services – all were small scale. Two studies were confined to a state-wide hospice survey,[20-21] and one focused on a sample from one medical centre only, resulting in overall small numbers of hospices, clinicians and patient records included.[22] In addition, the majority of the data from all studies was limited to clinicians’ perceptions only, with limited objective data and no patient or carer experiences captured.

**DISCUSSION**
This review found sparse research in this area: 9 of the 10 studies were small-scale or pilot studies and local samples. Although it is difficult to generalise the results, this review identified several problems with current models and also highlighted potential approaches to improving medicine access.

Overall findings suggest there are problems with accessing medicines via community pharmacies, and a number of issues delaying access have been identified, many of which focus on either pharmacy stock, or communication between the pharmacy and health professionals, and with patients. However, with the exception of one study (Ise et al), sample sizes were small and pertain to only a few localities, and there is a lack of data on outcomes of access experiences.

Wider literature also reports deficiencies in community pharmacy stock of palliative medicines [23] and in our review we found pharmacies commissioned to provide stocks of locally agreed palliative medication lists reduced delays in medicine access and tailored lists produced through communication between pharmacies and GPs worked similarly.[17] However, this study evaluated only one local service and city area; thus, evaluation of these services on a wider scale is warranted.

Alternatively, improvements upstream in the supply chain to community pharmacies might also be effective in avoiding potential delays – further research into the effectiveness of the supply chain of palliative care medicines is also required. Studies also suggested a number of problematic issues were linked to communication between pharmacists and patients (patients’ lack of awareness of services, and of opportunity for information-provision about medicines) and / or between pharmacists and other health professionals (pharmacists’ lack of awareness of patients’ palliative care status, health professionals’ lack of awareness of commissioned or enhanced pharmacy services). Patients’ and carers’ needs for information about medicines in this context have been repeatedly identified,[24-26] and the potential role of the pharmacist in fulfilling such needs also highlighted. For example, Latif et al recommend that pharmacists should elicit patient’s level of understanding,[27] their concerns about medicines and provide tailored information to ensure medicines optimisation. The review reported here suggests more proactive awareness-raising of
pharmacy services and more pharmacist engagement in information-giving continues to be required. To address the communication gap between community pharmacy and the wider healthcare team, greater integration of the pharmacist into the primary healthcare team would be advantageous. Calls for such actions for the pharmacy profession have been made in other contexts.[28] Our review also suggests there may be a case for improved training and education or support for community pharmacists and GPs as well as counter staff and locum pharmacists, a recommendation made elsewhere in relation to generalists and specialist palliative care medicines.[29-30] Further to the problems identified in this area in their 2012 study, Akram et al (2017) also reported a promising initiative of a specialist palliative care pharmacist who provided education for, and facilitated involvement of, community pharmacists in palliative care locally.[31] This kind of approach might assist collaboration among community healthcare professionals and support better information provision; the model of a specialist palliative care community pharmacist has recently been recommended in national policy in this area.[32] Wider examination of this area is warranted.

Three studies in this review suggested that HEMKs - kits comprised of a number of palliative care medicines stored in the patient’s home that could be used in an emergency - can avert hospital admissions and emergency department visits and improve quality of care at home by providing timely access during out-of-hours. Accessing services and medicines out-of-hours is known to be particularly problematic and a focus for service delivery recommendations,[33] and so the use of such kits in the home offers a promising way to deal with this. A qualitative evaluation of HEMKs introduced in an Australian setting [34] adds to the positive data on this form of service delivery: caregivers ‘overwhelmingly’ (p486) viewed the introduction of the kit into the home as positive, citing accessibility, timeliness and symptom control as benefits. Although the study also reported some carers lacked confidence and expressed concerns about administration of medicines in the home, an issue which the studies in the review reported here did not explore. Although a more limited form of ‘just-in-case’ medicine kits are used in the UK in the last few days of life, more data is needed to consider the applicability of HEMKs in the context of different healthcare systems.

Couriering of medicines and the ability of palliative care patients and carers to be involved in collecting prescriptions or medicines was raised in two studies.[17-18] Solutions such as electronic prescribing and transfer to the pharmacy (in the UK, a system which now includes prescription of controlled drugs) and home delivery may be of value to overcome this. But one study (Kuruvilla et al) highlighted that delivery systems are not free-of-charge and reduce contact time with the pharmacist, and a more recent survey highlighted electronic prescribing is far from universally
available to prescribing nurses and pharmacists suggesting further in-depth evaluation of these aspects of service delivery is required.[35]

Community palliative care specialist nurse prescribers were also reported to provide out-of-hours support and quicker medicine access in times of crisis. This form of out-of-hours care delivery is also recommended as a quality improvement priority by Williams et al[36] following their review of community palliative care incidents reported on a national database. However, evaluative data in the review reported here were confined to one small scale study and therefore further evidence, including larger-scale studies and insights of other stakeholders, are needed to endorse the value of nurse and pharmacist prescribing in this context.

The review also highlights that a variety of indicators have been used to measure medicines ‘access’, including patient- and nurse-reported length of time to receive medicines, delay / no delay experienced, number of pharmacies visited, stock held by pharmacies, supply chain issues, whether information on medicines is provided, as well as characterisation of a range of influences on access and supporting access to medicines. Drawing these systematically together may be useful in informing the design of future research and service evaluations of interventions to promote better access to medicines in the community setting.

Any overall conclusions of the review are limited by the quantity and quality of the research included in the review. Only a few models were studied, and only one study used a systems approach,[18] studying different components of service delivery as a whole – all other studies focused on one component only, which is not representative of how patients experience care and the process of accessing medicines - from prescription request through to dispensing, supply and information-giving about medicines in the home. Medicines access provision by professionals such as generalist community nurses and family doctors are under-studied, as well as more recent initiatives such as nurse, pharmacist and paramedic prescribing, and developments such as telephone support lines available out-of-hours. Most studies in the review were small scale and many only included access as part of a broader focus, thereby further reducing the available data. Some models of care delivery – for example hospice emergency kits and nurse prescribing – will vary between countries and therefore the transferability of findings across international systems of care delivery is also limited. Most studies focused on health professional self-report data and only four studies included views of patients.[16-19] There was very little data on outcomes of medicine access experiences and so comparison between models was not possible.
Strengths and limitations

To our knowledge, the review is the first to systematically analyse international studies on the important issue of experiences of accessing palliative care medicines in the community. The review included a comprehensive search of grey literature sources, as well as consultation with experts to ensure unpublished literature was identified.

As the review was part of a larger study focused on medicines access within different models of community palliative care provision, we had an *a priori* focus on service delivery models that determined the structure of our review. The focus on models of care provision makes extrapolation of findings to different international contexts difficult; countries differ for example in the prescriptive authority afforded to nurses and pharmacists and the extent to which electronic prescribing is available for health professional prescribers to use.

We did not exclude studies on the basis of quality assessment, and the review is limited by the quantity and quality of research in this area (see above). Studies used heterogeneous indicators to measure experiences and outcomes of medicines access - therefore comparisons between studies and models were not possible.

**CONCLUSIONS**

Despite suggestions that accessing palliative care medicines to manage symptoms at home is problematic for patients, there is very little large scale or in-depth research into these experiences and how models of service delivery influence access and subsequent clinical outcomes and health service use. Further research evaluating both established and more recent service delivery models is required, that includes patient and carer perspectives and the measurement of outcomes.

**Acknowledgements**

The authors thank Vicky Fenerty, the Research Engagement Librarian, at the University of Southampton for her advice on the search strategy for the review.

**Funding**

The review reported here formed part of a larger study evaluating *Access to Medicines for patients at end-of-life in the context of service delivery characteristics* (*ActMed*) [ISRCTN:12762104](https://www.isrctn.com/)
PROSPERO registration: CRD42017083563 Date of registration 18 December 2017

Protocol: https://www.journalslibrary.nihr.ac.uk/programmes/hsdr/165223/#/

This study is funded by the National Institute for Health Research (NIHR) [Health Services & Delivery Research programme] (project number 16/52/23). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Professor Richardson is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

Competing interests
None declared.

CONTRIBUTORS
All authors (MO, NC, JB, AR, MB, MS, SL) contributed to study design. MO performed the searches; MO, NC and SL contributed to data collection and data analysis. MO and SL drafted the article. NC contributed to writing of the article. All authors revised the article critically for important intellectual content and were responsible for approval of the final manuscript. SL is responsible for the overall content as guarantor(s).

Provenance and peer review Not commissioned; externally peer reviewed.

* I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in BMJ Supportive & Palliative Care and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.
Licence for Publication
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ Supportive and Palliative Care and any other BMJPG products and sublicences such use and exploit all subsidiary rights, as set out in our licence (http://group.bmj.com/products/journals/instructions-for-authors/licence-forms).
REFERENCES


Records identified through database\(^1\) search \( (n = 3627) \)

Expert consultation \( (n = 19) \)

Records after duplicates removed \( (n = 3341) \)

Records screened\(^2\) \( (n = 3331) \)

Records excluded \( (n = 3294) \)

Citation search \( (n = 11) \)

Full-text articles assessed for eligibility \( (n = 38) \)

Studies\(^3\) included in qualitative synthesis \( (n = 10) \)

- Quantitative studies: 5
- Qualitative studies: 4
- Mixed-methods studies: 1

Full-text articles excluded, with reasons \( (n = 27) \)

- E-3: Anticipatory or “just in Case” medicines = 4
- E-8: Studies evaluating professional capacities only = 4
- E-9: Service/support of medicine management at home = 10
- Ex: Not primary/secondary research = 9

\(^1\) Database; MEDLINE:1306+CINAHL:167+ PsycINFO:968+EMBASE:1186

\(^2\) The reason for reduction; sources were not accessible: 10

\(^3\) Two papers reporting the same study were counted as one study
### Figure 1: Phase 1 study inclusion and exclusion criteria

**Inclusion criteria:**
- Studies evaluating patients’, carers’, and health professionals’ experiences and outcomes of medicine access processes specific to or inclusive of palliative and EoL care being provided to adult patients living in their own homes
- EoL: the last year of life
- Medicine access: prescribing, dispensing, supplying and providing associated information about medicines
- Prescribed medicines (excluding diagnostic tests, medical devices and medical materials) •
  Published in English language
- Published between January 2006 - March 2019 (June 2019 for Cochrane Database of Reviews and Grey Literature sources)

**Exclusion criteria:**
- Services for or related to children
- Services for in-patients or not-at-home care (e.g. nursing home, hospital wards)
- Services or support for medicines management within the home
- Research related to anticipatory, or ‘just-in-case’, medicines to control symptoms in the last days of life exclusively*
- Geographical medicine access in low economic countries not transferable to the UK **
- Evaluation of professional capacities for supporting medicines access processes

*In the United Kingdom, and internationally, ‘just-in-case’ medicines refer to a well-established practice of a few core medicines for mostly sub-cutaneous administration being placed in the home in case these are needed for symptom management in the last few days of life. As just-in-case medicines pertain only to this limited time frame and do not involve access processes as defined here, these were excluded from the review.

** Exclusion was based on a study focus on geographical access to medicines, which we considered materially different than the focus of our review. Whilst issues of geographical access were often associated with low economic countries, we did exclude any study on the basis of the country in which it was conducted.
Online supplemental material Table 1. Search terms for MEDILINE(EBSCO)

| S1 | (MH "Palliative Care") |
| S2 | (MH "Terminal Care") |
| S3 | palliative n3 care |
| S4 | terminal N3 care |
| S5 | "end of life" or EOL |
| S6 | palliat* |
| S7 | terminal and patients |
| S8 | medicat* |
| S9 | medicine* |
| S10 | drug* |
| S11 | (MH "Pharmacies") |
| S12 | (MH "Community Pharmacy Services") |
| S13 | access* |
| S14 | suppl* |
| S15 | dispens* |
| S16 | distribut* |
| S17 | availab* |
| S18 | deliver* |
| S19 | administ* |
| S20 | "out of hours" |
| S21 | prescri* |
| S22 | pharmac* |
| S23 | primary N3 care |
| S24 | primary health care |
| S25 | home |
| S26 | communit* |
| S27 | general practice |
| S28 | (MH "General Practice") |
| S29 | "Family practice" |
| S30 | local N3 Pharmac* |
| S31 | "Community practice" |
| S32 | Community N3 Pharmac* |
| S33 | S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 |
| S34 | S8 OR S9 OR S10 |
| S35 | S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 |
| S36 | S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 |
| S37 | S33 AND S34 AND S35 AND S36 |

Limiters: - Date of Publication: 20060101-20180331; English Language; Human; Age Related: All Adult: 19+ years

MH: medical subject headings, N3: allowing 0 to 3 words between the words
### Online supplemental material Table 3. Quality assessments of included studies.

<table>
<thead>
<tr>
<th>Qualitative studies</th>
<th>1.1. Is the qualitative approach appropriate to answer the research question?</th>
<th>1.2. Are the qualitative data collection methods adequate to address the research question?</th>
<th>1.3. Are the findings adequately derived from the data?</th>
<th>1.4. Is the interpretation of results sufficiently substantiated by data?</th>
<th>1.5. Is there coherence between qualitative data sources, collection, analysis and interpretation?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akram et al. 2012</td>
<td>Yes</td>
<td>Verbatim transcription</td>
<td>Framework Analysis</td>
<td>Yes Quotation is adequately employed for each theme.</td>
<td>Yes</td>
</tr>
<tr>
<td>Bennie et al. 2013</td>
<td>Yes</td>
<td>Can’t Tell No description of the topic guide.</td>
<td>Can’t Tell No description of the method of qualitative analysis</td>
<td>Yes Quotation is adequately employed for each theme.</td>
<td>Yes</td>
</tr>
<tr>
<td>Kuruvilla et al. 2018</td>
<td>Yes</td>
<td></td>
<td>Framework Analysis</td>
<td>Yes Quotation is adequately employed for each theme.</td>
<td>Yes</td>
</tr>
<tr>
<td>Latham and Nyatanga 2018</td>
<td>Can’t Tell Full details of purposive sampling not given. Interview schedule validation unclear.</td>
<td></td>
<td>Constant comparative method is reasonable for interpretative phenomenology.</td>
<td>Yes Quotation is adequately employed for each theme.</td>
<td>Yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quantitative studies</th>
<th>4.1. Is the sampling strategy relevant to address the research question?</th>
<th>4.2. Is the sample representative of the target population?</th>
<th>4.3. Are the measurements appropriate?</th>
<th>4.4. Is the risk of nonresponse bias low?</th>
<th>4.5. Is the statistical analysis appropriate to answer the research question?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
<td>Analysis</td>
<td>Sampling Process</td>
<td>Description of Sample</td>
<td>Survey Question</td>
<td>Data Collection Method</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------</td>
<td>------------------</td>
<td>-----------------------</td>
<td>----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Lucey et al 2008</td>
<td>Yes</td>
<td>All GPs, pharmacists in one city area; all patients over a 3 month period in the hospice; unclear details of if / how nurses were sampled.</td>
<td>Can't Tell Details of respondents are not given, other than as part of the target sample</td>
<td>Can't Tell Details of the development of the questionnaires are not given</td>
<td>No Response rates were: GPs 41%; pharmacists 33% and patients 38.5%.</td>
</tr>
<tr>
<td>Bishop et al 2009</td>
<td>Yes</td>
<td>Sampling process is adequate; surveyed all active programs in the target area</td>
<td>Can't Tell Clear description of the sample and reasonable as a local study but difficult to understand if generalisable across country or globally.</td>
<td>Yes The survey question was reviewed by a third party and seems to be reasonable. Data collection method of telephone interview was not described.</td>
<td>Yes All candidates were contacted and response rate of the survey was 22/22. Results from 1 program were not included due to limited response.</td>
</tr>
<tr>
<td>Walker and McPherson. 2010</td>
<td>Can't Tell 1) Sampling process for the survey is adequate; surveyed all active programs in the target area. 2) No details of the method of sampling hospices or nurses within them for the comparative study.</td>
<td>Can’t Tell 1) Details of survey respondent sample and hospices are lacking. 2) No details of hospices or nurses taking part in the comparative study are given.</td>
<td>Yes 1) Survey questions seem to be reasonable though it was only internally reviewed. Data collection method of telephone interview was not described. 2) Methods for comparing frequency, estimated cost and client satisfaction were reasonable.</td>
<td>Yes 1) 21/23 programs in the area participated and 14 reported using EMK 2) No details are given on response rates of nurses in the hospices</td>
<td>Yes</td>
</tr>
<tr>
<td>Ise et al. 2010</td>
<td>Yes</td>
<td>Random sampling from a community pharmacist database</td>
<td>Yes Clear description of the sample with adequate methods.</td>
<td>Yes The survey question was clearly defined and seemed to be reasonable though it was only internally reviewed.</td>
<td>No Response rate was low at 34.5%.</td>
</tr>
</tbody>
</table>
Leigh et al. 2013

- Method: Mixed-method study
- 5.1. Is there an adequate rationale for using a mixed method design to address the research question? **Can’t Tell**
- 5.2. Are the different components of the study effectively integrated to answer the research question? **No**
- 5.3. Are the outputs of the integration of qualitative and quantitative components adequately interpreted? **Can’t Tell**
- 5.4. Are divergences and inconsistencies between quantitative and qualitative results adequately addressed? **No**
- 5.5. Do the different components of the study adhere to the quality criteria of each tradition of the methods involved? **Yes**

Only 77% had cared for a veteran with the institution’s HEMK. Reasons why eligible individuals chose not to participate were not described. Response rate of the questionnaire was 49% (78/160); authors acknowledge there may have been a positive response bias.

Miller 2017

- Method: Mixed-method study
- 5.1. Is there an adequate rationale for using a mixed method design to address the research question? **Yes**
- 5.2. Are the different components of the study effectively integrated to answer the research question? **Yes**
- 5.3. Are the outputs of the integration of qualitative and quantitative components adequately interpreted? **Yes**
- 5.4. Are divergences and inconsistencies between quantitative and qualitative results adequately addressed? **Can’t tell** Divergences and inconsistencies were not described in much detail.
- 5.5. Do the different components of the study adhere to the quality criteria of each tradition of the methods involved? **Yes**

1) QUAN (Observational study): The sampling strategy was reasonable but limited participants.
2) QUAL (interviews): There was a clear description and reasonable methods.
## Online supplemental material Table 1 Details of included studies

<table>
<thead>
<tr>
<th>Reference, country</th>
<th>Model/s of service delivery</th>
<th>Study Aim and Design</th>
<th>Participants and sample size</th>
<th>Results and findings related to access</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lucey et al. 2008 Ireland</td>
<td>Specialist palliative home care, including community pharmacy, General Practice and specialist home care nursing.</td>
<td>A systems analysis to highlight factors causing delays in the process of obtaining medications for patients under the care of a specialist palliative home care provider.</td>
<td>1) Survey 111 GPs registered in North Dublin 57 Retail pharmacists registered in North Dublin 22 patients who were referred to one hospice home care team 2) Observational cohort study (12 reports by nurses in specialist care team)</td>
<td>1) Perceived factors causing delay in medicine access process:  <strong>GPs:</strong> need to clarify the advice given by the home care team (30.6%); the inability of someone to collect the prescription (23.4%); the patient being unable to attend the surgery (18.9%)  <strong>Pharmacists:</strong> some specialist palliative care medications were not stocked (49.1%), difficulty in obtaining the supply of these types of medications (33%); medication not being available on the medical reimbursement system (GMS) (49%)  <strong>Patient results:</strong> received their medication without delay (54%); had not been advised to change their medication by the home care team (46%) 2) Nurse reported 12 delays &gt; 24 hours over a 12 week period; 11 delays were &gt; 48 hours, and 6 delays were due to medication not being in stock. 86% of agencies reported HEMK often averted hospital or emergency department visits.</td>
</tr>
<tr>
<td>Bishop et al. 2009 USA</td>
<td>Hospice emergency medication kit (HEMK)</td>
<td>To survey all active hospice programs about their use of HEMKs</td>
<td>22 Clinical nurse directors or nurse managers in one state</td>
<td>1) 14 of 21 hospices reported using HEM. Perceived value of HEMK were preventing emergency department visits (69%), unscheduled nursing visits (54%) and pharmacy deliveries (77%) as well as increased satisfaction of both patients and nurses (both 100%). 2) Estimated time to symptom relief was shorter in Hospice A (with kits) patients than in Hospice B; Hospice A =56% received symptom relief within 30 minutes but Hospice B: none were satisfactorily treated in the same duration.</td>
</tr>
<tr>
<td>Walker and McPherson 2010 USA</td>
<td>Hospice emergency medication kit (HEMK)</td>
<td>To compare perceptions of hospice managers and clinicians regarding the value of Emergency Medication Kit (HEMK) and to assess outcomes</td>
<td>1) 21 Clinical directors (or equivalent) at hospices in one state 2) Hospice A (with HEMK) = 154 patients Hospice B (without HEMK) = 103 patients</td>
<td>1) 14 of 21 hospices reported using HEM. Perceived value of HEMK were preventing emergency department visits (69%), unscheduled nursing visits (54%) and pharmacy deliveries (77%) as well as increased satisfaction of both patients and nurses (both 100%). 2) Estimated time to symptom relief was shorter in Hospice A (with kits) patients than in Hospice B; Hospice A =56% received symptom relief within 30 minutes but Hospice B: none were satisfactorily treated in the same duration.</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Setting/Method</td>
<td>Sample Size</td>
<td>Findings/Actions</td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------</td>
<td>---------------------------------</td>
<td>-------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ise et al. 2010 Japan</td>
<td></td>
<td>Community pharmacy Quantitative Questionnaire survey</td>
<td>1036 community pharmacies as a representative national sample, (response rate: 34.5%).</td>
<td>After-hours nurses perceived caller satisfaction was significantly higher in Hospice A patients with a HEMK compared to both Hospice B and Hospice A patients without a HEMK. 77% of community pharmacies had a narcotics retailer license, 50% received prescriptions for and prepared narcotics each month. Half of the pharmacists reported that they did not counsel patients, primarily because they lacked information about the patient. Pharmacists reported communicating with terminally ill cancer patients was extremely difficult. 76% of community pharmacists felt it was important to be able to return opioids to wholesalers to make opioids more easily available to patients.</td>
</tr>
<tr>
<td>Akram et al. 2012 UK</td>
<td></td>
<td>Community pharmacy Understand the provision of enhanced service to community pharmacies (Community Pharmacy Palliative Care Network pharmacies offered specialised palliative medicines stock, urgent medicines delivery services and support to other health care professionals) Qualitative Focus group interviews</td>
<td>35 pharmacists in 5 focus groups</td>
<td>Barriers for pharmacists providing palliative care medicines in community pharmacy: 1) Medication supply stock issue; medicines not listed; out-of-hours prescriptions; prescribing error with controlled drugs; infrequent use of delivery service provided by other staff 2) Communication  - Communication issues across the palliative care team (e.g. necessity of contacting pharmacy in advance to prevent supply problems, poor communication during transition of hospital admission/discharge)  - Membership in the CPPC Network was seen as supportive but also meant unfamiliar patients were referred to them 3) Education and training</td>
</tr>
<tr>
<td>Source</td>
<td>Type</td>
<td>Methodology</td>
<td>Participants</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Bennie et al.</td>
<td>Community pharmacy</td>
<td>To investigate how older palliative care patients and their carers access</td>
<td>14 patients (aged 65–79)  13 carers (aged 57–74) took part in six separate focus</td>
<td></td>
</tr>
<tr>
<td>2013</td>
<td></td>
<td>information about their medication and what knowledge they have of</td>
<td>groups.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>community pharmacy services</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Qualitative Focus group interviews</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>To evaluate Hospice Emergency Kit (HEK), medication utilization, safety,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>diversion and perceived impact</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>76 deceased veterans discharged to home hospice</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>78 hospice nurses in 16 community hospice agencies (49% response rate)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leigh et al.</td>
<td>Hospice emergency</td>
<td>To evaluate Hospice Emergency Kit (HEK), medication utilization, safety,</td>
<td>59% of the nurses felt HEMKs were helpful 100% of the</td>
<td></td>
</tr>
<tr>
<td>2013 USA</td>
<td>medication kits (HEMK)</td>
<td>diversion and perceived impact</td>
<td>time (mean 84.2%) and 93% felt an emergency visit or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>hospitalization was avoided by having the kit in the</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>home.</td>
<td></td>
</tr>
<tr>
<td>Miller 2017</td>
<td>Community pharmacy</td>
<td>To investigate the delivery of palliative care services by community</td>
<td>1) Stock availability led to delays: approximately 1 in 5</td>
<td></td>
</tr>
<tr>
<td>UK</td>
<td></td>
<td>pharmacists in Sheffield</td>
<td>customers had to go to more than one pharmacy to get urgently required</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mixed-methods Prescription analysis; customer survey; health care</td>
<td>palliative care medication, with one in two customers who were referred</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>professional interviews</td>
<td>by a healthcare professional needing to go to more than one pharmacy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2) No evidence that errors on prescriptions led to a delay in obtaining</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>palliative medication.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3) The median time taken for accessing urgent palliative care medicines</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>was significantly longer for non-commissioned service pharmacies (5 hours)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>compared to pharmacies commissioned to hold stock of palliative</td>
<td></td>
</tr>
</tbody>
</table>

- Limited understanding of the role by other PC team members
- Better training for counter assistants and locum pharmacist
- Availability of routine resource for pharmacists to support clinical practice (e.g. web-page)
  1) Access to medication information
  - Patient information leaflets appeared to be most common source of information about drugs
  - Participants preferred face-to-face interactions when possible
  2) Study participants had limited knowledge of available help for them from their community pharmacist regarding their medications; a more proactive role of community pharmacists in disseminating relevant and tailored information to older palliative care patients was desired.
### Kuruvilla et al. 2018 Australia
- **Community palliative care services**
- **To explore the perspective of stakeholders about gaps in the current model of community palliative care services and assess opinion on the role of a specialist palliative care pharmacist**
- **Qualitative Focus group interviews**
- **Healthcare professionals (n=12):**
  - 3 Palliative care medical consultants
  - 1 Palliative care medical registrar
  - 1 GP
  - 1 Palliative care nurse-consultant
  - 1 Palliative care nurse-practitioner
  - 2 Community nurses
  - 1 Hospital pharmacist
  - 1 Community pharmacist

**Palliative care patients/caregivers (n=8)**

**Themes from the focus groups:**
- **Gaps in access to medicines/resources / information:**
  - Lack of access to pharmacy stock, medicines information, and patient medical records, especially outside business hours and difficulties for patients living in rural and remote areas were particular barriers highlighted by focus group participants.

### Latham and Nyatanga 2018 UK
- **Community specialist nurse independent prescribers**
- **To explore the lived experience of clinical nurse specialists working as independent prescribers**
- **Qualitative Interviews**
- **6 Community specialist nurse non-medical independent prescribers**

**1) Perceived benefits of nurse independent prescribing:**
- A) Helping patients in times of crisis
- B) Being available when others are not (out-of-hours)

**2) Barriers to prescribing practice:**
- A) Anxiety about writing prescriptions incorrectly
- B) Inadequate knowledge and negative/unfavourable attitudes of other HCPs
- C) Inadequate access to patients’ medical information